Abstract: NUT midline carcinoma is an aggressive tumor that occurs mainly in the head and neck and, less frequently, the mediastinum and lung. Following identification of an index case of a NUTM1 fusion positive undifferentiated soft tissue tumor, we interrogated additional cases of primary undifferentiated soft tissue and visceral tumors for NUTM1 abnormalities. Targeted next-generation sequencing was performed on RNA extracted from formalin-fixed paraffin-embedded tissue, and results validated by fluorescence in situ hybridization using custom bacterial artificial chromosome probes. Six patients were identified: mean age of 42 years (range, 3 to 71 y); equal sex distribution; and, tumors involved the extremity soft tissues (N = 2), kidney (N = 2), stomach, and brain. On systemic work-up at presentation all patients lacked a distant primary tumor. Morphologically, the tumors were heterogenous, with undifferentiated roundepithelioid-rhabdoid cells arranged in solid sheets, nests, and cords. Mitotic activity was generally brisk. Four cases expressed pancytokeratin, but in only 2 cases was this diffuse. Next-generation sequencing demonstrated the following fusions: BRD4-NUTM1 (3 cases), BRD3-NUTM1, MXD1-NUTM1, and BCORL1-NUTM1. Independent testing by fluorescence in situ hybridization confirmed the presence of NUTM1 and partner gene rearrangement. This study establishes that NUT-associated tumors transgress the midline and account for a subset of primitive neoplasms occurring in soft tissue and viscera. Tumors harboring NUTM1 gene fusions are presumably underrecognized, and the extent to which they account for undifferentiated mesenchymal, neuroendocrine, and/or epithelial neoplasms is unclear. Moreover, the relationship, if any, between NUT-associated tumors in soft tissue and/or viscera, and conventional NUT carcinoma, remains to be elucidated.
N
UT midline carcinoma (also known as NUT carcinoma) is a clinically aggressive neoplasm that typically occurs in the head and neck 1 or mediastinum; 2,3 although more recently, there have been reports of primary lung, [4] [5] [6] and renal involvement. 7, 8 Considered rare, the actual incidence of NUT midline carcinoma is unknown, and presumably significantly underestimated. 9 While initial reports suggested a pediatric predisposition, increased recognition of this entity has led to broader characterization among adults. There is no obvious sex predisposition. 10 Over 80% of patients die within the first year of diagnosis of NUT carcinoma; 9 locoregional and distant metastases are common and, aside from complete surgical resection, there is currently limited therapeutic benefit from chemoradiotherapy. 9 NUT carcinoma is considered a genetically defined tumor, encompassing any malignant epithelial tumor neoplasm with rearrangement of NUTM1 (NUT [nuclear protein in testis] midline carcinoma family member 1 11 ). 1, 9 Despite uncertainty with respect to its underlying histogenesis, NUT carcinoma has been classified as a form of poorly differentiated carcinoma-possibly a subtype of squamous cell carcinoma 12 -based on the frequent presence of squamous differentiation. 1 The most common NUTM1 fusion partner is BRD4, which occurs in roughly 70% of cases; 13 the remaining cases are reported to pair with BRD3 13 or NSD3 (also known as WHSC1L1), 14 or with an, as of yet, undefined fusion partner(s), which is referred to as NUT-variant carcinoma. There does not presently appear to be a relationship between patient outcome and NUTM1 fusion partner. 9, 10 Next-generation sequencing is gradually becoming routinely applied in the diagnostic pathology laboratory.
Following the incidental discovery of an undifferentiated soft tissue tumor bearing a NUTM1 gene fusion by nextgeneration sequencing testing, we proceeded to examine additional undifferentiated soft tissue and visceral tumors for NUTM1 rearrangement.
MATERIALS AND METHODS

Case Selection
The index case in this study had undergone routine diagnostic RNA sequencing (RNASeq), which revealed NUTM1 rearrangement. As a result, retrospective archival searches were performed for other undifferentiated soft tissue and visceral tumors by the 2 senior authors (B.C.D./ C.R.A.; 2007 to 2017). Cases in which the soft tissues or viscera was purported to represent the site of primary disease were pulled for rereview. In view of the commonality of nuclear isomorphism among most translocation-associated tumors, only those cases that lacked significant pleomorphism were selected for RNASeq. This study received institutional Research Ethics Board approval.
Immunohistochemistry
The paraffin-embedded tissue blocks selected in all cases were confirmed to have adequate viable tumor, and all were properly formalin-fixed. Staining was performed for keratins (pancytokeratin, high-molecular and lowmolecular weight keratins), claudin-4, p63, S100, glial fibrillary acid protein, chromogranin, synaptophysin, actin, desmin CD34, and NUT using routine techniques (Supplementary Table 1 , Supplemental Digital Content 1, http:// links.lww.com/PAS/A587). Appropriate on-slide positive controls were used throughout. Tumor immunoreactivity was scored based on the percentage of positive cells (0, no staining; 1+, <5%; 2+, 5% to 25%; 3+, 26% to 50%; 4+, 51% to 75%; and 5+, 76% to 100%).
RNA Sequencing
Briefly, for each case scrolls (3 to 4 at 10 μm) were cut from formalin-fixed paraffin-embedded tissue into Eppendorf tubes. RNA was extracted using the ExpressArt FFPE Clear RNA Ready kit (Amsbio, Cambridge, MA). RNASeq libraries were prepared using 20 to 100 ng total RNA with the TruSight RNA Fusion Panel (Illumina, San Diego, CA), an enrichment-based assay that targets 507 known fusion-associated genes. Each sample was sequenced with 76 base-pair paired-end reads on an Illumina MiSeq at 8 samples per flow cell (∼3 million reads per sample). The results were analyzed using the STAR aligner and Manta fusion caller as well as the JAFFA fusion caller utilizing BOWTIE2 aligner. 15, 16 The mRNA expression levels of NUTM1, and the respective fusion partners, were evaluated and compared with those of other samples analyzed on the same targeted RNASeq platform.
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization for NUTM1 was performed on each case, followed by confirmation of each of the various fusion partners, including: BCORL1, BRD3, BRD4, and MXD1. Testing was performed as previously outlined in detail. 17 Briefly, custom bacterial artificial chromosome clone probes were designed to flank the target genes, based on the UCSC genome browser (http://genome. ucsc.edu), and obtained from BACPAC sources of Children's Hospital of Oakland Research Institute (Oakland, CA; http://bacpac.chori.org) (Supplementary Table 2 , Supplemental Digital Content 2, http://links.lww.com/PAS/A588). DNA from each bacterial artificial chromosome was isolated, then labeled with fluorochromes by nick translation. Slides were prepared using formalin-fixed paraffin-embedded tissue cut at 4 μm. The slides were deparaffinized, pretreated, and then hybridized with the denatured probes. Following an overnight incubation, the slides were rinsed, stained with 4',6-diamidino-2-phenylindole, mounted, and examined using a Zeiss fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany).
RESULTS
Six cases were identified from institutional pathology archives; 1 of the cases (patient 6) has previously been reported (Table 1 ). 8 The mean patient age was 42 years (range, 3 to 71 y). There were an equal number of females and males. Two tumors occurred in the extremity soft tissues and 2 in kidney, with individual cases involving brain (parietal lobe) and stomach wall (Table 1) .
Grossly, where details were available, the tumors were gray-tan-white with hemorrhagic foci; they ranged from firm-friable, with 1 case described as "fleshy." The margins tended to be infiltrative; the 2 soft tissue tumors were deep-seated and invaded surrounding skeletal muscle. The visceral lesions infiltrated into the brain and renal parenchyma; the gastric tumor was centered in the muscularis propria and extended to serosa. Microscopically, the (Fig. 3) ; and, 2 cases predominantly BRD3, and MXD1 (Table 2) . Independent testing by fluorescence in situ hybridization confirmed the presence of NUTM1 and partner gene rearrangement. Four cases demonstrated NUT immunoreactivity; immunopositivity was present in tumors with BRD4 and BRD3 gene fusions, but not in the 2 cases with the novel MXD1 and BCORL1 gene partners (Table 2 and Fig. 4 ). In 1 of the tumors, case 2, immunohistochemical studies were repeated on freshly cut sections from 2 different surgical resections and both were negative for NUT staining. The remaining immunohistochemical findings are detailed in Table 2 .
RNASeq demonstrated the presence of significant mRNA NUTM1 expression in all 4 cases tested, regardless of the fusion partner (Fig. 5) . Corresponding increases in mRNA expression among the fusion genes was observed for BCORL1 and MXD1, but not BRD3 or BRD4 (data not shown). The NUTM1 breakpoints were located at exon 5 (case 1; NCBI Reference Sequence: NM_001284292.1) and exon 3 (cases 2 to 3, 5 to 6; NM_001284292.1); the BRD3 breakpoint involved exon 9 (case 1; NM_007371.3); BCORL1 exon 1 (case 2; NM_021946.4); MXD1 exon 5 (case 3; NM_002357.3); and, BRD4 exon 11 (cases 5 to 6; Pt PanCK HMWK LMWK C-4 p63 S100 GFAP Syna Chro Actin Desmin CD34 NUT Molecular
*Diffuse strong immunoreactivity for CK7. 8 − indicates negative; C-4, Claudin-4; Chro, chromogranin; HMWK, high-molecular weight keratin; LMWK, low-molecular weight keratin; NA, not assessed; panCK, pancytokeratin; Pt, patient number; Syna, synaptophysin; w, weak. 
NM_058243.2). These results imply that an identical
NUTM1 breakpoint is present in BRD4, BCORL1, and MXD1; therefore, it appears that the specific breakpoint is unlikely to be a factor in the variable NUT protein expression identified by immunohistochemistry.
On systemic work-up at initial presentation, none of the patients had evidence of a distant primary tumor. However, all patients subsequently developed lymph node and/or lung metastases. Patient 4, with a locally recurrent brain tumor, did not reveal evidence of extraneural disease on autopsy. At last follow-up, all except 1 patient had succumbed to disease, with 4 patients dying within the first year of diagnosis. The only patient still alive after 108 months, despite peritoneal dissemination and lymph node metastases, had a MXD1-NUTM1 fusion (Table 1) .
DISCUSSION
NUT midline carcinoma is a relatively recently recognized entity, 3, [18] [19] [20] [21] and considered among the most aggressive of human solid malignancies. 22 Tumors tend to be distributed along the midline axis with a predilection for the head and neck, and mediastinum and lung. In addition, there are rare reports of primary bladder, 23 breast, 23 endometrium, 23 kidney, 7, 8 and orbit 23 involvement. There is a propensity for early metastases to lymph nodes and lung, and tumors are almost inevitably fatal. Following discovery of an index case of an undifferentiated soft tissue tumor containing NUTM1 rearrangement, we sought to investigate the incidence of NUTM1-related fusions among undifferentiated tumors in the soft tissue and viscera. In addition to identifying primary NUTM1-rearanged undifferentiated tumors in the soft tissue extremities, kidney, stomach, and brain, we report 2 novel NUTM1 fusion partners.
Our study cohort was characterized by a markedly heterogenous phenotype, which lacked defining morphologic and/or immunohistochemical attributes. As is typical of most tumors characterized by reciprocal translocations, none manifested diffuse pleomorphism. Common architectural patterns included sheets, nests, and cords of undifferentiated cells; the tumors were infiltrative, lacking "pushing" borders. The cells varied from small to large; epithelioid, round, rhabdoid, and ovoid shapes were common. Necrosis was frequently present. In contrast to NUT midline carcinoma, which typically express cytokeratin expression, 23, 24 only a minority of our cases showed significant keratin positivity; none of the tumors in this series contained overt squamous differentiation in the form of keratinization. In addition, only a single case showed significant expression of claudin-4, a tight junction-associated protein expressed in most epithelial cells. 25 NUT midline carcinoma has been reported to express CD34, CD99, and synaptophysin. In our series, in addition to occasional synaptophysin expression, we identified the presence of glial fibrillary acid protein expression in several cases.
Notably, 2 of the cases in our series were negative for NUT by immunohistochemical testing. Each case was confirmed to contain abundant viable tumor that had been properly formalin-fixed and paraffin-embedded. In a previous series of NUT midline carcinoma NUT immunohistochemical testing, using a similar clone, was found to have a sensitivity of 87%, with 4 cases reported to be falsely negativity. 26 In that study 2 of the cases were, on rereview, found to be weakly positive, with 1 possibly attributable to postmortem degradation; both of the negative cases were NUT-variant carcinoma, leading the authors to suggest variant fusion proteins may be expressed at lower levels than the BRD3 and BRD4 fusion products. Interestingly, the 2 negative cases in our series corresponded to the 2 novel NUTM1 fusion partners (BCORL1-NUTM1 and MXD1-NUTM1). By illustrating the presence of high levels of mRNA expression in all cases examined (Fig. 5C ), our findings raise the possibility that, in a subset of cases, a posttranscriptional mechanism may account for the absence of NUT staining by immunohistochemistry.
The sole pediatric patient in our series, presenting as a left parietal lobe tumor in a 3-year-old male, deserves further discussion. Because of its primitive morphology, this tumor was initially classified generically as a highgrade neuroepithelial neoplasm with embryonal features/ PNET. This diagnosis was supported by focal GFAP and synaptophysin positivity. Given the combination of embryonal-appearing small cell components, alveolar pattern with myxoid growth and evidence of NUT expression we considered whether this unusual lesion might be related to the neoplasms recently described as CNS Ewing Family Tumors with CIC-NUTM1 fusions. 27 On methylation profiling, however, this neoplasm did not cluster with tumors of the CNS Ewing Family Tumor CIC group or with any other embryonal or other neuroepithelial tumors included in the array algorithm (data not shown).
On the basis of frequent keratin expression it has been concluded NUT midline carcinoma represent a carcinoma. 23 The presence-often with abrupt transition -of squamous keratinization has further led to classification of NUT midline carcinoma as a subtype of squamous cell carcinoma. 28 Mesenchymal differentiation is reported to rarely occur. 29 Admittedly, keratin expression alone does not establish a diagnosis of carcinoma and it is a relatively consistent feature of several sarcomas (eg, epithelioid sarcoma, desmoplastic small round cell tumor, and synovial sarcoma). Undifferentiated small round cell tumors such as Ewing sarcoma, and those with BCOR rearrangement have also been reported to show keratin, epithelial membrane antigen, and p63 expression. [30] [31] [32] [33] The relationship between NUT-associated tumors of soft tissue, or viscera, and NUT midline carcinoma remains unclear. Some of the cases in the current series (patients 1 and 5) bore morphologic and immunohistochemical overlap with reports of NUT midline carcinoma in the literature. This raises the possibility that at least some of the cases in this series fall under the rubric of NUT midline carcinoma. However, anatomic distribution notwithstanding, the morphology of 2 of the tumors is distinct from the histologic spectrum heretofore described in NUT midline carcinoma. For example, 1 case (patient 2) had areas resembling myoepithelial carcinoma, sclerosing epithelioid fibrosarcoma, and fibrosarcoma; this same patient also had PNET-like features, in addition to well-formed rosettes. The immunophenotype of the tumors in this series also appears to somewhat differ from the literature on NUT midline carcinoma. For example, in contrast to NUT midline carcinoma, where keratin positivity is frequently diffuse, only 2 cases in this series appeared to have significant keratin expression. Expression of p63 is likewise common in NUT midline carcinoma, but only observed in 2 cases in this series. Our cases possessed NUTM1 breakpoints similar to those previously reported; 18, 34 nevertheless, given differences in anatomic distribution, morphology and immunophenotype-and uncertainty regarding underlying histogenesis-we feel it prudent to classify the neoplasms in this series as a NUTassociated tumor, rather than NUT midline carcinoma.
The incidence of NUT-associated tumors is unknown, and it is presumed that cases in the soft tissue and viscera have heretofore gone unrecognized. In a series of unclassified malignancies and poorly differentiated carcinomas of the mediastinum, 3.5% were found to represent NUT midline carcinoma. 35 Another series examining poorly differentiated carcinomas in children and young adults demonstrated an incidence of 7%. 23 It is unclear if this range is similar for tumors occurring in the soft tissue and viscera. In addition to BRD4 and BRD3, we identified 2 novel NUTM1 fusion partners: BCORL1 and MXD1. Whether either of these genes accounts for any of the unknown gene partners in NUT-variant carcinoma remains to be determined. The protein encoded by BCORL1 (BCL6 corepressor-like 1) is a transcriptional corepressor homolog of BCOR; it is capable of interacting with class II histone deacetylases and CtBP to mediate transcriptional repression. 36 Translocations involving BCORL1 have been previously reported in hepatocellular carcinoma, 37 ossifying fibromyxoid tumor, 38 and endometrial stromal sarcoma. 39 The protein encoded by MXD1 (MAX dimerization protein 1) is a transcriptional repressor and it is a member of the MYC/MAX/MAD transcription family, with roles in apoptosis, differentiation, and proliferation. 40, 41 The MYC/MAX/MAD network is important in the development of numerous malignancies, including, for example, neural crest tumors such as subsets of pheochromocytoma and neuroblastoma. 42 To our knowledge mutations, including translocations, involving MXD1 have not been reported to date.
In summary, we report 6 cases of primary undifferentiated tumors occurring in the soft tissue and viscera (brain, kidney, stomach wall) associated with NUTM1 rearrangement, and 2 novel NUTM1 fusion partners (BCORL1 and MXD1). Despite some overlap with NUT midline carcinoma, the tumors in this series differed in several regards, including: anatomic distribution, morphology, and immunophenotype; of particular relevance is the fact that definitive evidence of epithelial differentiation could not be established among many of our cases. As a result, we have tentatively labeled these malignant neoplasms a NUTassociated tumor. It is conceivable this may represent an overarching category that also includes NUT midline carcinoma.
The authors recently encountered a third case of primary soft tissue NUT-associated tumor arising in a 16-yearold male as a large, deep-seated thigh mass (21 cm), encasing the distal femur with areas of intramedullary involvement. Morphologically, the tumor showed predominantly an epithelioid/rhabdoid phenotype, with focal areas of round/ primitive cell features. Immunohistochemically, the tumor was negative for cytokeratins and NUT. Targeted RNA sequencing, further confirmed by FISH, showed the presence of a NSD3-NUTM1 fusion, as previously reported. 14 
